Renal Cancer

Renal Cancer
2025-01-10T06:29:55.066Z

XL092-304

XL092-304
Renal cancer

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma. Study detail: This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy

A study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (STELLAR-304)

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Renal cancer

Study Phase

III

Trial registration
GenesisCare Location(s)
GenesisCare Location(s)
Medical Oncologist

Dr Mark McGregor

BMBS FRACP B.Pharm (Hons)

Dr Mark McGregor
location pin icon

Elizabeth Vale at Calvary Central Districts Hospital (Oncology)

View Profile
Profile Image - Dr  Mark  McGregor

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.